Polyclonal Anti-T-Lymphocyte Globulin (ATG) in Type 1 Diabetes

  • STATUS
    Recruiting
  • participants needed
    28
  • sponsor
    Institute for Clinical and Experimental Medicine
Updated on 7 November 2020
Investigator
Frantisek Saudek, MD.
Primary Contact
Institute for Clinical and Experimental Medicine, Department of Diabetes (1.2 mi away) Contact
diabetes
insulin
body mass index
fasting
glucagon
autoimmune disease
c-peptide

Summary

The primary objective of the study is: - To compare the effect of ATG treatment together with intensified insulin therapy (Group 1) on fasting and glucagon-stimulated C-peptide production with that of intensified insulin therapy only (Group 2) in type 1 diabetes mellitus of recent onset Secondary objectives are: - To compare the insulin doses between the two groups at 6, 12, 18, and 24 months after diabetes onset - To compare the course of the specific humoral markers of autoimmunity between the groups - To evaluate the significance of in vitro testing of specific T-cell activation by an autoantigen in the long-term follow-up in type 1 diabetes - To assess the safety of ATG treatment in type 1 diabetes

Description

This is a randomized, controlled, single-blind and parallel group study. After admission to the hospital, initial physical and laboratory examinations will be performed. Laboratory tests and medical treatment not related to the experimental protocol (except for immunosuppressive drugs) will be performed as clinically needed. Patients who fulfill the inclusion criteria and give their informed consent to participate in the study will be randomized to be treated either with a course of ATG-Fresenius together with intensified insulin therapy (Group 1) or with intensified insulin therapy only (Group 2). For the study purpose, clinical and laboratory status of the patients will be assessed at 14 occasions (screening, visit 1 – visit 14). Thereafter, an extended follow-up study is planned with evaluations every 6 months. Patients will be referred to the research institution by cooperating general practitioners and diabetes specialists, preferably before initiation of insulin therapy. After diabetes confirmation (according to WHO criteria) and initial clinical and biochemical examinations (typical for all patients with recent onset diabetes) the purpose, potential risk and benefits and the design of the study will be explained. Subjects willing to participate in the study will be asked to give their written informed consent. All patients will be actively educated in diabetes management and intensified insulin therapy (3 – 4 daily injections of human insulin, glucose self-monitoring) will be initiated according to individual needs. In subjects randomized to Group 1, 4 doses of ATG Fresenius (first dose of 9 mg/kg of body weight, then 3 consecutive doses of 3 mg/kg) will be administered intravenously over 4 hours. Subjects in Group 2 will be treated with saline infusion (500 ml) on the same days. 1 hour before the first ATG administration, a cutaneous tolerance test (0.2 ml of the final solution) will be performed. Approximately 10 days after admission the patients will be dismissed. Besides scheduled ambulant visits, all subjects will be followed-up as clinically needed. In Paediatric patients (age 15-18 years), recommendations of a paediatric endocrinologist concerning diabetes management will be respected. After completion of the study each patient’s diabetes specialist will be acquainted with the course of the treatment so far and the patients will be treated according to individual needs. They will be seen regularly once per year in the Department of Diabetes in IKEM for the next 3 years. Discontinuation of the study: Participation in the study may be at all times stopped according to the patient’s will. Should this require the medical status of the patients, the study may be interrupted based on the investigator’s decision during the period of ATG administration. Study population: Twenty four patients with type 1 diabetes mellitus of recent onset will be followed in the Institute for Clinical and Experimental Medicine in Prague. Inclusion criteria will be: - Type 1 diabetes mellitus of known duration up to 6 weeks - Men and women 15 – 35 years old, body mass index up to 32 kg/m2, exclusion of gravidity in women - Insulin dose up to 40 IU per day for no longer than 1 month - C-peptide level ≥ 0.3 pmol/ml 4 min. following iv. administration of 1 ml glucagon - No previous immunosuppressive therapy, no concurrent severe infection, granulocyte count ≥ 2 x 10^9/l, platelet count ≥ 120 x 10^9/l

Details
Condition Insulin dependent diabetes mellitus
Treatment Polyclonal anti-T-cell antibodies
Clinical Study IdentifierNCT00190502
SponsorInstitute for Clinical and Experimental Medicine
Last Modified on7 November 2020

Eligibility

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note